In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to identify Risk-free dosing program. Extra members will be enrolled with the discovered monotherapy dosign program. In Segment B, members will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Segment C, participants https://dallastepzk.blognody.com/32942549/top-latest-five-brd4-targeted-therapy-abbv-744-clinical-data-urban-news